EUVIMEDEUVIMED entdecken
Crossref

Skinny Labels at the Supreme Court—Generic Competition, Patent Inducement, and Affordable Medicines

S Sean Tu, Frazer A Tessema, Aaron S Kesselheim

JAMA · 05.05.2026 · 335 (17) · 1475

DOI: 10.1001/jama.2026.3526 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA, erschienen am 05.05.2026. Verfasst von S Sean Tu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Wo…. Die Arbeit nennt 6 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This Viewpoint discusses use of skinny labeling to reduce the price of brand-name drugs, impediments to timely generic market entry and affordability, and inducement liability that causes marketing uncertainty.

Autor:innen und Institutionen

  • Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
  • University of Alabama School of Law, Tuscaloosa.
  • Department of Medicine, University of Chicago, Chicago, Illinois.

Zitieren

APA

Tu, S. S., Tessema, F. A., & Kesselheim, A. S. (2026). Skinny Labels at the Supreme Court—Generic Competition, Patent Inducement, and Affordable Medicines. JAMA, 335(17), 1475. https://doi.org/10.1001/jama.2026.3526

Vancouver

Tu SS, Tessema FA, Kesselheim AS. Skinny Labels at the Supreme Court—Generic Competition, Patent Inducement, and Affordable Medicines. JAMA. 2026;335(17):1475. doi:10.1001/jama.2026.3526

BibTeX
@article{Tu2026,
  author = {Tu, S Sean and Tessema, Frazer A and Kesselheim, Aaron S},
  title = {Skinny Labels at the Supreme Court—Generic Competition, Patent Inducement, and Affordable Medicines},
  journal = {JAMA},
  year = {2026},
  volume = {335},
  number = {17},
  pages = {1475},
  doi = {10.1001/jama.2026.3526}
}
Kostenlos starten →